BioMed Central Cancer
Neoadjuvant chemotherapy is a key component of breast cancer treatment regimens and pathologic complete response to this therapy varies among patients. This is presumably due to differences in the molecular mechanisms that underlie each tumor’s disease pathology. Developing genomic clinical assays that accurately categorize responders from non-responders can provide patients with the most effective therapy for their individual disease. We applied our previously developed E2F4 genomic signature to predict neoadjuvant chemotherapy response in breast cancer. E2F4 individual regulatory activity scores were calculated for 1129 patient samples across 5 independent breast cancer neoadjuvant chemotherapy datasets. Accuracy of the E2F4 signature in predicting neoadjuvant chemotherapy response was compared to that of the Oncotype DX and MammaPrint predictive signatures.
Mark, Kenneth M. K.; Varn, Frederick S.; Ung, Matthew H.; Qian, Feng; and Cheng, Chao, "The E2F4 Prognostic Signature Predicts Pathological Response to Neoadjuvant Chemotherapy in Breast Cancer Patients" (2017). Open Dartmouth: Faculty Open Access Articles. 575.